Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of light dose on efficacy of 5-ALA photodynamic therapy for actinic keratoses
2015-002245-66Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of 5-aminolevulinic acid in actinic keratosis (AK) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Complete clearance of actinic keratoses at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2015-002245-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002245-66.